OKYO Pharma (NASDAQ:OKYO) announced that the U.S. Food and Drug Administration has authorized a single-patient expanded access Investigational New Drug application (IND 176297) for urcosimod 0.05% to treat a patient with severe neuropathic corneal pain (NCP).
ImmunityBio (NASDAQ:IBRX) reported updated Phase 2 clinical results for its novel immunotherapy combination in patients with recurrent glioblastoma, suggesting the treatment may overcome the "immune collapse" that typically follows standard cancer therapies.
Plus Therapeutics (NASDAQ:PSTV) on Thursday detailed a strategic shift toward "pivotal trial readiness," supported by a recently completed $15 million public offering designed to extend the company’s cash runway into 2027.
Janux Therapeutics (NASDAQ:JANX) shares surged as much as 12% in early trading Thursday following the announcement of a global licensing deal with Bristol Myers Squibb (NYSE:BMY) worth up to $850 million.
Abbott Laboratories (NYSE:ABT) set a confident tone for 2026, projecting a return to double-digit earnings growth and robust organic sales as it prepares to integrate a massive new cancer-diagnostics vertical.
Greenwich LifeSciences (NASDAQ:GLSI) shares jumped Thursday morning after the clinical-stage biotech announced that the U.S. Food and Drug Administration (FDA) has approved the use of its first commercially manufactured lot of GP2 vials in the ongoing FLAMINGO-01 Phase III trial.
Lexicon Pharmaceuticals (NASDAQ:LXRX) successfully completed an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration for its lead pain candidate, pilavapadin.
Dr. Reddy’s Laboratories (NYSE:RDY) reported fiscal third-quarter revenue that surpassed analyst expectations Wednesday, as explosive growth in emerging markets and a resilient domestic business in India helped offset a steep decline in its North American generic portfolio.
Revelation Biosciences (NASDAQ:REVB) announced it has reached a milestone agreement with the FDA on an "expedient" approval pathway for Gemini, its lead candidate for the treatment of Acute Kidney Injury (AKI).
Lisata Therapeutics (NASDAQ:LSTA) shares soared Wednesday morning after the clinical-stage biotech announced a binding agreement to be acquired by privately held Kuva Labs.
Ionis Pharmaceuticals (NASDAQ:IONS) and Otsuka Pharmaceutical achieved a major regulatory victory Wednesday as the European Commission (EC) granted marketing authorization for DAWNZERA (donidalorsen).
Johnson & Johnson (NYSE:JNJ) shares rose Wednesday after the healthcare giant capped a record-breaking 2025 with a major fourth-quarter earnings beat and issued a bold 2026 forecast that projects annual sales exceeding the $100 billion mark for the first time.
